Bafna Pharmaceuticals Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 342.18 million compared to INR 204.6 million a year ago. Revenue was INR 356.31 million compared to INR 209.47 million a year ago. Net income was INR 29.95 million compared to INR 17.03 million a year ago. Basic earnings per share from continuing operations was INR 1.26 compared to INR 0.72 a year ago. Diluted earnings per share from continuing operations was INR 1.26 compared to INR 0.72 a year ago.
For the nine months, sales was INR 731.06 million compared to INR 701.58 million a year ago. Revenue was INR 764.62 million compared to INR 709.92 million a year ago. Net income was INR 59.66 million compared to INR 61.66 million a year ago. Basic earnings per share from continuing operations was INR 2.51 compared to INR 2.55 a year ago. Diluted earnings per share from continuing operations was INR 2.51 compared to INR 2.55 a year ago.